Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
Amazon Web Services Expands Bedrock GenAI Service
April 23, 2024
Why Microsoft Stands Out As A Pre-Earnings Buy
April 23, 2024
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
BNTX Stock News and Mentions of BioNTech SE Stocktwits
Updated: April 25, 2024 (01:57)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where BioNTech Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of BioNTech SE (BNTX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the BioNTech stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of BioNTech SE (BNTX)
April 23, 2024 (19:00) / "Benzinga" (by Vandana Singh)
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown - Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London patent trial concerning the development of COVID-19 vaccines. The High Court is slated to address a legal complaint brought by Moderna.
In Article Trend: Neutral
April 22, 2024 (10:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT ( 2:00 ...
In Article Trend: Neutral
April 21, 2024 (04:44) / "Barrons" (by Yassine KHIRI)
InstaDeep CEO Takes AI From Tunis To London
Karim Beguir launched the artificial intelligence start-up InstaDeep in Tunisia in 2014 with just two computers and $2,000. By 2023, it was an international operation bought by German laboratory BioNTech for $700 million.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:13) / "Benzinga" (by Caleb Naysmith)
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert - CureVac ( NASDAQ:CVAC ) , BioNTech ( NASDAQ:BNTX )
Bill Gates warned about the risk of pandemics well before COVID-19. In 2018, he predicted that "there is a significant probability of a large and lethal, modern-day pandemic occurring in our lifetimes" because of "the continual emergence of new pathogens, the increasing risk of a bioterror attack ...
In Article Trend: Somewhat-Bearish
April 12, 2024 (10:30) / "Forbes" (by Giacomo Tognini)
Meet The Billionaire-Owned Company Making Injectors For Blockbuster Drugs Like Ozempic
Billionaire-Owned SHL Medical Makes Injectors For Drugs Like Ozempic Forbes ...
In Article Trend: Neutral
April 11, 2024 (13:12) / "Zacks Commentary" (by Zacks Equity Research)
Will Novavax's ( NVAX ) Strategic Reshaping Curb Cash Burn?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
In Article Trend: Neutral
April 11, 2024 (13:12) / "Zacks Commentary" (by Zacks Equity Research)
Will Pfizer's ( PFE ) New Drugs Provide a Boost to 2024 Sales?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
In Article Trend: Somewhat-Bullish
April 7, 2024 (18:00) / "GlobeNewswire" (by BioNTech SE)
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
MAINZ, Germany, April 7, 2024 - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy ( "iNeST" ) candidate autogene cevumeran ( also known as BNT122, RO7198457 ...
In Article Trend: Neutral
April 4, 2024 (16:18) / "Benzinga" (by Vandana Singh)
CureVac, GS Partner Release Data On Influenza Vaccine Study - CureVac ( NASDAQ:CVAC ) , GSK ( NYSE:GSK )
CureVac N.V. CVAC released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc GSK.
In Article Trend: Neutral
April 4, 2024 (09:00) / "GlobeNewswire" (by Medigene AG)
Medigene AG Secures European Patent for its iM-TCR Technology
Planegg/Martinsried, April 4, 2024. Medigene AG ( Medigene, FSE: MDG1, Prime Standard ) , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (09:00) / "Benzinga" (by Globe Newswire)
Medigene AG Secures European Patent for its iM-TCR Technology
Planegg/Martinsried, April 4, 2024.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:29) / "CNN" (by Eva Rothenberg)
US scientists are leaving academia. That's bad news for drug companies | Business
US scientists are leaving academia. That's bad news for drug companies ...
In Article Trend: Neutral
March 28, 2024 (06:30) / "GlobeNewswire" (by Medigene AG)
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
Planegg/Martinsried, March 28, 2024. Medigene AG ( Medigene or the "Company", FSE: MDG1, Prime Standard ) , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the fiscal year ended December ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (20:05) / "GlobeNewswire" (by Matinas BioPharma Holdings)
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions ...
In Article Trend: Neutral
March 27, 2024 (20:05) / "Benzinga" (by Globe Newswire)
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update - Matinas BioPharma Hldgs ( AMEX:MTNB )
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal ...
In Article Trend: Neutral
March 27, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Posts Upbeat Data From Next-Gen COVID Jab Study
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
In Article Trend: Neutral
March 21, 2024 (01:24) / "Money Control"
Wall Street ends higher as Fed keeps three rate cuts on the horizon
The Fed's policy statement described inflation as remaining "elevated," and it raised economic projections for economic growth and lowered its projection for the unemployment rate from estimates it provided in December.
In Article Trend: Neutral
March 20, 2024 (18:45) / "Motley Fool" (by Motley Fool Transcribing)
BioNTech Se ( BNTX ) Q4 2023 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:38) / "Benzinga" (by Upwallstreet)
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials - BioNTech ( NASDAQ:BNTX )
BioNTech SE BNTX is way past its glorious Covid-19 days, when it thrived with Pfizer Inc PFE for saving the world from the pandemic with their jointly developed vaccine.
In Article Trend: Neutral
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (15:49) / "Benzinga" (by Henry Khederian)
Why Moderna Shares Are Falling - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA shares are trading lower by 2.7% to $102.25 during Wednesday's session in possible sympathy with BioNTech, which reported worse than expected fourth-quarter earnings. In the fourth-quarter of fiscal year 2023 BioNTech SE reported lower earnings and sales than the previous year.
In Article Trend: Neutral
March 20, 2024 (13:09) / "Investors Business Daily" (by Investor's Business Daily)
BioNTech Dives As Sales Crash 65%, Missing Forecasts
BioNTech Stock Dives After Sales Plummet 65% And Miss Forecasts Investor's Business Daily ...
In Article Trend: Neutral
March 20, 2024 (12:43) / "Benzinga" (by Vandana Singh)
Why Is BioNTech Stock Trading Lower On Wednesday? - BioNTech ( NASDAQ:BNTX )
Pfizer Inc's PFE German partner, BioNTech SE BNTX, reported fourth-quarter 2023 EPS of fiscal year Q4 GAAP EPS of €1.90 versus €9.26, a year ago, equivalent to $2.04 missing the consensus of $2.64.
In Article Trend: Neutral
March 20, 2024 (11:44) / "Barrons" (by Brian Swint)
BioNTech Earnings Miss Estimates. The Stock Falls and Also Drags Moderna Lower.
BioNTech Earnings Fall Short of Estimates. The Stock Is Down. ...
In Article Trend: Somewhat-Bearish
March 20, 2024 (11:28) / "Benzinga" (by Shanthi Rexaline)
Why Nasdaq, S&P 500 Futures Are Muted Today - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Investors remain cautious ahead of the Federal Reserve's interest rate decision, with stock futures on Wednesday hinting at a lower opening. Trading is expected to be subdued, mirroring the historical pattern on Fed decision days. Stocks may stagnate until the announcement is released.
In Article Trend: Neutral
March 20, 2024 (10:15) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
• Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 • Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech's strategy to develop combinatorial and ...
In Article Trend: Neutral
March 20, 2024 (10:00) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Mainz, Germany, March 20, 2024 ( GLOBE NEWSWIRE ) - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
In Article Trend: Somewhat-Bullish
March 20, 2024 (08:42) / "Barrons" (by Joe Woelfel)
Intel, Chipotle, Nvidia, PDD, Mobileye, Signet, BioNTech, and More Stock Market Movers
Chipotle, Nvidia, JetBlue, Micron, Gildan Activewear, and More Stock Market Movers ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (09:25) / "Motley Fool" (by James Brumley)
3 Stocks I'm Adding to My Retirement Account in March
A handful of names offer a combination of reliability and opportunity that many other stocks don't right now.
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:57) / "Benzinga" (by Globe Newswire)
The Gross Law Firm Notifies BioNTech SE Investors of a Class Action Lawsuit and Upcoming Deadline - BNTX
NEW YORK, March 12, 2024 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
In Article Trend: Somewhat-Bearish
March 11, 2024 (17:55) / "Benzinga" (by Globe Newswire)
BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 11, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE BNTX between March 30, 2022 and October 13, 2023, both dates inclusive ( the "Class Period" ) , of the important March 12, 2024 lead plaintiff ...
In Article Trend: Neutral
March 11, 2024 (16:24) / "Benzinga" (by Globe Newswire)
FINAL DEADLINE REMINDER FOR BNTX INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against BioNTech SE ( BNTX ) - BioNTech ( NASDAQ:BNTX )
RADNOR, Pa., March 11, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE ( ...
In Article Trend: Neutral
March 11, 2024 (15:38) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for DADA, BNTX, and CMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Cummins ( NYSE:CMI ) , BioNTech ( NASDAQ:BNTX )
LOS ANGELES, March 11, 2024 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
March 11, 2024 (11:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
MAINZ, Germany, March 11, 2024 - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research ( "AACR" ) Annual Meeting 2024 in San Diego, California, from April 5-10, ...
In Article Trend: Neutral
March 11, 2024 (10:25) / "PR Newswire" (by The Gross Law Firm)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTX
NEW YORK, March 11, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
In Article Trend: Somewhat-Bearish
March 11, 2024 (08:00) / "Benzinga" (by Globe Newswire)
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 11, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or "the Company" ) BNTX and certain of its officers.
In Article Trend: Neutral
March 9, 2024 (02:00) / "Benzinga" (by Globe Newswire)
BIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 08, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or the "Company" ) BNTX in the United States District Court for the ...
In Article Trend: Neutral
March 7, 2024 (18:45) / "Benzinga" (by Globe Newswire)
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE ( BNTX ) - BioNTech ( NASDAQ:BNTX )
LOS ANGELES, March 07, 2024 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP ( "GPM" ) reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioNTech SE ( "BioNTech" or the ...
In Article Trend: Neutral
March 7, 2024 (11:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Planned Retirement of Sean Marett
Mainz, Germany, March 7, 2024 ( GLOBE NEWSWIRE ) - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.
In Article Trend: Somewhat-Bullish
March 7, 2024 (10:51) / "Benzinga" (by Globe Newswire)
Omics-Based Clinical Trials Market to Reach USD 54.42 Billion to 2031 | InsightAce Analytic
Jersey City, NJ, March 07, 2024 ( GLOBE NEWSWIRE ) -- InsightAce Analytic Pvt.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
MAINZ, Germany, March 6, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at ...
In Article Trend: Neutral
March 6, 2024 (11:11) / "CNN" (by Mira Cheng)
A man deliberately got 217 Covid shots. Here's what happened
One German man has redefined "man on a mission." A 62-year-old from Magdeburg deliberately got 217 Covid-19 vaccine shots in the span of 29 months, according to a new study, going against national vaccine recommendations. That's an average of one jab every four days.
In Article Trend: Neutral
March 6, 2024 (10:00) / "GlobeNewswire" (by Medigene AG)
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
Planegg/Martinsried, March 6, 2024. Medigene AG ( Medigene or the "Company", FSE: MDG1, Prime Standard ) , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer ...
In Article Trend: Neutral
March 6, 2024 (02:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm - BioVie ( NASDAQ:BIVI ) , Archer-Daniels Midland ( NYSE:ADM )
NEW YORK, March 05, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioNTech SE BNTX, Mobileye Global Inc. MBLY, BioVie Inc.
In Article Trend: Neutral
March 5, 2024 (16:50) / "Benzinga" (by Globe Newswire)
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioNTech SE ( BNTX ) Shareholders - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 05, 2024 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ( "BioNTech" or the "Company" ) BNTX of a class action securities lawsuit.
In Article Trend: Neutral
March 4, 2024 (22:33) / "Benzinga" (by Globe Newswire)
BioNTech SE investors: Please contact the Portnoy Law Firm to recover your losses; March 12, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises BioNTech SE ( "BioNTech" or the "Company" ) BNTX investors that a lawsuit was filed on behalf of investors that purchased B.
In Article Trend: Neutral
March 4, 2024 (17:06) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for DADA, BNTX, and CMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Cummins ( NYSE:CMI ) , BioNTech ( NASDAQ:BNTX )
LOS ANGELES, March 04, 2024 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
March 4, 2024 (14:44) / "Benzinga" (by Benzinga Insights)
5 Value Stocks In The Healthcare Sector - Innoviva ( NASDAQ:INVA ) , BioNTech ( NASDAQ:BNTX )
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (09:00) / "Benzinga" (by Globe Newswire)
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 04, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or "the Company" ) BNTX and certain of its officers.
In Article Trend: Neutral
March 4, 2024 (07:00) / "GlobeNewswire" (by Medigene AG)
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
Planegg/Martinsried, March 4, 2024. Medigene AG ( Medigene, FSE: MDG1, Prime Standard ) , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office ...
In Article Trend: Neutral
March 4, 2024 (07:00) / "Benzinga" (by Globe Newswire)
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
Planegg/Martinsried, March 4, 2024.
In Article Trend: Neutral
March 3, 2024 (14:50) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE ... PR ...
In Article Trend: Neutral
March 3, 2024 (03:02) / "Business Insider" (by NEWSFILE)
BNTX DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
BNTX DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action ...
In Article Trend: Neutral
March 2, 2024 (02:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm - BioVie ( NASDAQ:BIVI ) , Archer-Daniels Midland ( NYSE:ADM )
NEW YORK, March 01, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioNTech SE BNTX, Mobileye Global Inc. MBLY, BioVie Inc.
In Article Trend: Neutral
March 2, 2024 (00:46) / "Benzinga" (by Globe Newswire)
Important March 12, 2024 Deadline Reminder for BioNTech SE Investors: Kessler Topaz Meltzer & Check, LLP Reminds BioNTech SE ( BNTX ) Investors of Securities Fraud Class Action Lawsuit - BioNTech ( NASDAQ:BNTX )
RADNOR, Pa., March 01, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE ( ...
In Article Trend: Neutral
February 29, 2024 (19:20) / "MarketWatch" (by Jeremy C. Owens)
Nvidia's next mission: Make even more financial history
No company has ever posted financial results quite like Nvidia's, but that just means Wall Street now expects the Silicon Valley chip maker to do something else that has never been done.
In Article Trend: Somewhat-Bullish
February 29, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Down 0.2% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
February 29, 2024 (07:07) / "Benzinga" (by Benzinga Neuro)
CDC Urges Second COVID-19 Vaccine Dose For Elderly Americans Amid Rising Hospitalizations
The Centers for Disease Control and Prevention ( CDC ) has recommended a second annual COVID-19 vaccine for individuals aged 65 and above. This decision comes in the wake of a significant increase in COVID-19 hospitalizations among older Americans.
In Article Trend: Neutral
February 28, 2024 (17:46) / "Stocknews.com" (by StockNews.com Staff)
BNTX: 3 Biotech Stocks to Watch in March for Success
The biotech industry is thriving due to consistent innovations and the sustained demand for cutting-edge healthcare solutions. Additionally, the industry benefits from a fast-aging demographic and an expanding need for high-quality treatments for both rare and common diseases, which contribute to ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (15:22) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX - BioNTech ( NASDAQ:BNTX )
NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or the "Company" ) BNTX. The class action, filed in the United States District Court for the Central District of California, and docketed under ...
In Article Trend: Neutral
February 28, 2024 (00:49) / "Benzinga" (by Globe Newswire)
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX - BioNTech ( NASDAQ:BNTX )
NEW YORK, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE BNTX between March 30, 2022 and October 13, 2023, both dates inclusive ( the "Class Period" ) , of the important March 12, 2024 lead plaintiff ...
In Article Trend: Neutral
February 27, 2024 (15:51) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for MSS, ASRT, DADA, BNTX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - Assertio Holdings ( NASDAQ:ASRT ) , BioNTech ( NASDAQ:BNTX )
BENSALEM, Pa., Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
February 27, 2024 (02:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm - BioVie ( NASDAQ:BIVI ) , Archer-Daniels Midland ( NYSE:ADM )
NEW YORK, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioNTech SE BNTX, Mobileye Global Inc. MBLY, BioVie Inc.
In Article Trend: Neutral
February 26, 2024 (17:16) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for DADA, BNTX, and CMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Cummins ( NYSE:CMI ) , BioNTech ( NASDAQ:BNTX )
LOS ANGELES, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
February 26, 2024 (15:27) / "Benzinga" (by Globe Newswire)
BNTX NEWS: Johnson Fistel Encourages BioNTech Investors to Seek Counsel Before the Lead Plaintiff Deadline - BioNTech ( NASDAQ:BNTX )
SAN DIEGO, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- Johnson Fistel, LLP notifies investors of BioNTech SE BNTX that a securities class action lawsuit has been filed.
In Article Trend: Neutral
February 26, 2024 (10:45) / "PR Newswire" (by The Gross Law Firm)
Shareholders that lost money on BioNTech SE ( BNTX ) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Shareholders that lost money on BioNTech SE ( BNTX ) Urged to Join Class Action - Contact The Gross Law Firm to ... PR ...
In Article Trend: Somewhat-Bearish
February 26, 2024 (09:00) / "Benzinga" (by Globe Newswire)
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - BioNTech ( NASDAQ:BNTX )
NEW YORK, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or "the Company" ) BNTX and certain of its officers.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website